A 66-year-old lady presented to the outpatient clinic because of progressive normochromic macrocytic anemia of nine months duration, causing fatigue, weakness and malaise. She was treated, before her admission, with intramuscular vitamin B$_{12}$ and per os folic acid administration, and after a slight first increase, the hemoglobin decreased again to 8.0 g/dL. The diagnosis was refractory macrocytic anemia and the patient needed occasional blood transfusions. Her past medical history included vagotomy since 15 years ago, and tuberculosis in childhood, without a history to toxic agents’ exposure. Her mother died due to breast cancer and her father with acute myeloid leukemia.

Physical examination on admission revealed palor, a few small cervical lymph nodes (smaller than 0.5 cm in diameter, mobile and inflexible) and a mild splenomegaly (3 cm below costal margin).

The hematological profile was as follows: Ht 28.6%, Hb 8.7 g/dL, (MCV 107 fl, MCH 33.9 pg, MCHC 30.4 g/dL), reticulocytes 2.5%, WBC 3.8×10$^{9}$/L (neutrophils 46%, lymphocytes 38%, monocytes 15%, eosinophils 1%), platelet count 620×10$^{9}$/L. Macrocytosis, anisocytosis, poikilocytosis and few giant platelets were observed on routine blood smears (fig. 1). Her biochemical profile was as follows: SGOT 30 IU/L, SGPT 45 IU/L, LDH 850 IU/L, glucose 1.0 g/dL, BUN 0.50 g/dL, creatinine 1.2 mg/dL, uric acid 7.5 g/dL, Na$^{+}$ 139 mEq/L, K$^{+}$ 4.0 mEq/L, Ca$^{2+}$ 4.8 mEq/L, γ-GT 38 IU/L, total proteins 7.4 g/L, protein electrophoresis was normal. Serum vitamin B$_{12}$ was 450 ng/L, while serum folate was 8.3 μg/L. Serum Fe/ferritin levels were normal. Serum erythropoietin (EPO) concentration was 564 IU/L. The bone marrow aspiration revealed hypercellular marrow with erythroid hyperplasia and megaloblastic and moderate dyserythropoietic changes. The myeloid series was normal, the blast count was less than 5% and many hypolobulated or unilobulated megakaryocytes with platelet clumps were also present (figures 2, 3). The cytogenetic analysis was characteristic in most of the bone marrow metaphases.

The patient was treated with EPO administration, on alternate days, at a dose of 150 U/kg, which was increased to 300 IU/kg after 6 weeks.

Comment

5q- syndrome is an association of refractory anemia with the presence of morphological abnormal megakaryocytes in the bone marrow and long arm deletion of chromosome 5 (non-specific finding). Typically, the syndrome is frequent in persons (more frequent in women) over 60 years of age (<25% in persons less than 50 years of age, rarely in younger persons). Diagnosis is confirmed
The main manifestation is a progressive presence of a mild macrocytic anemia (hemoglobin less than 8 g/dL in 50% of cases), while thrombocytopenia with a normal or mild decrease of WBC usually exists. There is also intense anisocytosis, poikilocytosis, as well as the presence of giant platelets in the peripheral blood smear.

There is an increased megakaryocytic number in the bone marrow, with frequent finding of micromegakaryocytes, with one nucleus or decreased nuclear lobes or containing a cleaved nucleus, or 2−3 lobes overlapped and abundant cytoplasm (platelet producing megakaryocytes). Mononuclear megakaryocytes may also be seen in chronic myelogenous leukemia (CML), but they represent only a small percentage of megakaryocytes. Bone marrow cellularity varies and there is often an erythroid series hyperplasia. In in vitro cultures, there is a normal CFU-GM growth but a diminished BFU-E growth. Clinically, about 25% of the patients have splenomegaly.

The most frequent abnormality is related to the areas between 5q12 and 5q33 [more often del(5)(q13q33) and in most cases the deletion of a region near the 5q22]. The GM-CSF, IL-3 and IL-5 related genes and M-CSF, platelet-derived growth factor and endothelial cell growth factor receptors are placed in this region. The abnormality is located mainly in the myeloid series cells and not in T lymphocytes, stromal cells and other cell types (main role of these factors synthesis). In addition to 5q- other abnormalities of chromosomes 3, 7, 8, 17 and 21 have been described (with an atypical syndrome and, rather, as having an acute leukemia or preleukemia).

References


Corresponding author:
J. Meletis, Hematology Department and Bone Marrow Transplantation Unit, National and Kapodistrian University of Athens, School of Medicine, “Laiko” General Hospital, Athens, Greece, tel.: +30 210 74 66 902, fax: +30 210 7456698 e-mail: imeletis@med.uoa.gr